Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
Tinostamustine (EDO-S101) comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Tinostamustine||EDO-S101|EDOS101|EDO S101||Chemotherapy - Alkylating 14 HDAC Inhibitor 38||Tinostamustine (EDO-S101) comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594, PMID: 32099034, PMID: 31372848).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Tinostamustine||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with EDO-S101 induced apoptosis and decreased viability of a multiple myeloma cell line in culture (PMID: 28753594).||28753594|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03687125||Phase Ib/II||Tinostamustine||Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1)||Terminated|
|NCT02576496||Phase I||Tinostamustine||Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies||Recruiting|
|NCT03345485||Phase Ib/II||Tinostamustine||Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors||Active, not recruiting|
|NCT03452930||Phase I||Tinostamustine||Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma||Recruiting|